NICE Clinical Guideline 79

Rheumatoid arthritis: the management of rheumatoid arthritis in adults

The recommendations from NICE cover:
  • pharmacological management including:
    • introduction and withdrawal of disease-modifying anti-rheumatic drugs
    • short- and long-term treatment with glucocorticoids
    • symptom control
  • referral for specialist treatment
  • monitoring of rheumatoid arthritis.
 
Web address: www.nice.org.uk/Guidance/CG79

NICE Clinical Guideline 80

Early and locally advanced breast cancer

The recommendations from NICE cover:
  • non-pharmacological and pharmacological treatments including:
    • under-the-arm surgery
    • breast reconstruction if breast conservation is not an option
    • endocrine, chemotherapy, and biological treatments
  • complications of local treatment and
    menopausal symptoms.
 
Web address: www.nice.org.uk/Guidance/CG80

NICE Clinical Guideline 81

Advanced breast cancer

The recommendations from NICE cover:
  • the key priorities for implementation
  • management of complications, including:
    • lymphoedema
    • cancer-related fatigue
    • uncontrolled local disease
  • provision of information and support for decision making
  • systematic disease-modifying therapy.
 
Web address: www.nice.org.uk/Guidance/CG81

NICE Technology Appraisal 167

Abdominal aortic aneurysm—endovascular stent-grafts

Summary:
  • endovascular stent-grafts are recommended as an option for people with abdominal aortic aneurysms if:
    • the aneurysm occurs below the kidney but has not ruptured
    • surgery is considered to be appropriate and the specialist has discussed the risks and benefits of all the alternatives with the patient, and both have decided endovascular stent-grafts are the best option
  • endovascular stent-grafts are not recommended for patients whose abdominal aortic aneurysm has ruptured unless they are taking part in research.
 
Web address: www.nice.org.uk/Guidance/TA167

NICE Technology Appraisal 168

Influenza—zanamivir, amantadine and oseltamivir (review)

Summary:
  • oseltamivir and zanamivir are recommended as possible treatments for the treatment of influenza in adults and children if all of the following circumstances apply:
    • the person is in an ‘at-risk’ group
    • treatment can be started within 48 hours (or within 36 hours for zanamivir treatment in children) of onset of first symptoms of an influenza-like illness
    • national surveillance schemes indicate that influenza virus A or B is circulating
  • amantadine is not recommended for the treatment of influenza.
 
Web address: www.nice.org.uk/Guidance/TA168